NO20051111L - Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse - Google Patents

Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse

Info

Publication number
NO20051111L
NO20051111L NO20051111A NO20051111A NO20051111L NO 20051111 L NO20051111 L NO 20051111L NO 20051111 A NO20051111 A NO 20051111A NO 20051111 A NO20051111 A NO 20051111A NO 20051111 L NO20051111 L NO 20051111L
Authority
NO
Norway
Prior art keywords
nitrogen
monounsaturated
amino group
heterocyclic compound
containing heterocyclic
Prior art date
Application number
NO20051111A
Other languages
English (en)
Inventor
Andrew V Schally
Attila A Nagy
Ren-Zhi Cai
Original Assignee
Tulane Educat Fund Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20051111(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tulane Educat Fund Inc filed Critical Tulane Educat Fund Inc
Publication of NO20051111L publication Critical patent/NO20051111L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Fremgangsmåte for omdanning av nitrogenet i en primær aminogruppe i et primært <x,p eller a,y-hydroksyamin til nitrogenet i en mono-umettet, nitrogenholdig heterocyklisk forbindelse med mellom 5 og 6 atomer i ringen, der fremgangsmåten omfatter trinnene: a) behandling av hydroksyaminet med et overskudd av et halogenaldehyd med et aldehydkarbon,et halogen-bærende karbon og med 2 eller 3 deler mellom aldehydkarbonet og det halogen-bærende karbon valgt blant CH, CHCHog OCHb) tilsetning av et overskudd, beregnet på hydroksyaminet, av en organisk base c) nøytralisering av basen med en svak syre, og d) behandling med en fortynnet, vandig syre.
NO20051111A 1995-11-27 2005-03-01 Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse NO20051111L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (1)

Publication Number Publication Date
NO20051111L true NO20051111L (no) 2005-03-01

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19982252A NO324035B1 (no) 1995-11-27 1998-05-15 Antracyklin-analoger samt blandinger og anvendelser derav
NO20051111A NO20051111L (no) 1995-11-27 2005-03-01 Fremgangsmate for omdanning av nitrogen i en primaer aminogruppe til nitrogen i en monoumettet, nitrogenholdig, heterocyklisk forbindelse

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19982252A NO324035B1 (no) 1995-11-27 1998-05-15 Antracyklin-analoger samt blandinger og anvendelser derav

Country Status (27)

Country Link
US (2) US5843903A (no)
EP (2) EP0863917B1 (no)
JP (2) JP3987575B2 (no)
KR (2) KR100467899B1 (no)
CN (2) CN1166597C (no)
AT (2) ATE401305T1 (no)
AU (1) AU709539B2 (no)
BR (1) BR9611647B1 (no)
CA (2) CA2238574C (no)
CZ (1) CZ297297B6 (no)
DE (2) DE69630233T2 (no)
DK (2) DK1384710T3 (no)
EA (1) EA001372B1 (no)
ES (2) ES2205067T3 (no)
HK (1) HK1052920B (no)
HU (1) HU229870B1 (no)
IL (3) IL134685A (no)
IS (2) IS2178B (no)
MX (1) MX9804119A (no)
NO (2) NO324035B1 (no)
NZ (1) NZ322054A (no)
PL (3) PL191781B1 (no)
PT (2) PT863917E (no)
SK (2) SK284392B6 (no)
UA (1) UA67722C2 (no)
WO (1) WO1997019954A1 (no)
ZA (1) ZA969709B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
ATE419273T1 (de) 1998-11-13 2009-01-15 Cyclacel Ltd Translokationsvektoren abgeleitet von der antennapedia homeodomain helix 3
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
CA2388844A1 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
ES2274823T3 (es) 1999-12-29 2007-06-01 Immunogen, Inc. Agentes cototoxicos que comprenden doxorrubicinas y daunorrubicinas y su utilizacion terapeutica.
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
WO2001081426A2 (en) * 2000-04-26 2001-11-01 Biosynthema Inc. Rgd (arg-gly-asp) coupled to (neuro)peptides
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
PL369336A1 (en) * 2001-09-21 2005-04-18 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
BR0308090A (pt) 2002-03-01 2006-04-11 Univ Tulane conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
ES2615484T3 (es) * 2002-05-21 2017-06-07 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen grelina
CA2484761C (en) 2002-05-24 2010-11-09 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
JP2006515186A (ja) 2002-09-26 2006-05-25 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 血管周囲ラップ
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
CA2523197C (en) * 2003-04-22 2016-05-24 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Peptide vectors
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
JP5340155B2 (ja) * 2006-09-06 2013-11-13 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞結合分子を有するジソラゾールのコンジュゲート及びそれらの誘導体、新規ジソラゾール誘導体、それらの製法ならびに使用
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
AU2009235897B2 (en) * 2008-04-11 2012-04-12 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof
KR101328315B1 (ko) * 2008-04-11 2013-11-11 티안진 헤메이 바이오-텍 컴퍼니 리미티드 고활성의 안트라사이클린 항생물질 유도체, 이의 제조방법 및 사용
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
CA2752608A1 (en) 2009-02-20 2010-08-26 Ipsen Pharma S.A.S. Cytotoxic conjugates having neuropeptide y receptor binding compound
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
ES2533710T3 (es) 2010-12-02 2015-04-14 Nerviano Medical Sciences S.R.L. Proceso para la preparación de derivados de morfolinil antraciclina
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
WO2016004048A2 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
HK1259311A1 (zh) 2015-10-28 2019-11-29 Tva (Abc), Llc Sstr靶向綴合物及其顆粒和製劑
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
AU2019469641B2 (en) * 2018-11-13 2025-04-03 Provincial Health Services Authority Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
EP4499663A1 (en) 2022-03-25 2025-02-05 Provincial Health Services Authority Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
FI102355B1 (fi) * 1988-02-11 1998-11-30 Bristol Myers Squibb Co Menetelmä yhdistävän välikappaleen omaavien antrasykliini-immunokonjugaattien valmistamiseksi
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ES2094136T3 (es) * 1989-12-19 1997-01-16 Pharmacia Spa Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
DK0450461T3 (da) * 1990-04-06 1995-10-23 Univ Tulane LHRH-analoger
ATE124054T1 (de) * 1990-04-06 1995-07-15 Univ Tulane Somatostatinanaloge.
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
AU7572296A (en) 1997-06-19
PT1384710E (pt) 2008-10-08
CA2238574C (en) 2004-10-19
DK1384710T3 (da) 2008-11-17
WO1997019954A1 (en) 1997-06-05
DE69630233T2 (de) 2004-08-05
KR19990071672A (ko) 1999-09-27
IS2178B (is) 2006-12-15
UA67722C2 (en) 2004-07-15
SK62898A3 (en) 1999-06-11
HUP9903771A3 (en) 2000-07-28
PL326865A1 (en) 1998-10-26
EP0863917B1 (en) 2003-10-01
BR9611647B1 (pt) 2010-03-09
HUP9903771A2 (hu) 2000-02-28
CZ135798A3 (cs) 1998-10-14
NZ322054A (en) 1999-04-29
CN1202903A (zh) 1998-12-23
KR20040037176A (ko) 2004-05-04
HK1052920A1 (en) 2003-10-03
EP0863917A1 (en) 1998-09-16
IL119691A (en) 2002-02-10
IS2634B (is) 2010-06-15
CN1405127A (zh) 2003-03-26
CZ297297B6 (cs) 2006-11-15
EP1384710B1 (en) 2008-07-16
ATE251179T1 (de) 2003-10-15
IL134685A (en) 2002-12-01
AU709539B2 (en) 1999-09-02
NO982252D0 (no) 1998-05-15
ZA969709B (en) 1997-08-25
IL134685A0 (en) 2001-04-30
PL188786B1 (pl) 2005-04-29
NO324035B1 (no) 2007-07-30
EA001372B1 (ru) 2001-02-26
KR100445754B1 (ko) 2004-12-08
US6184374B1 (en) 2001-02-06
PL191781B1 (pl) 2006-07-31
HK1052920B (zh) 2005-03-04
ES2205067T3 (es) 2004-05-01
EP1384710A1 (en) 2004-01-28
JP4778405B2 (ja) 2011-09-21
KR100467899B1 (ko) 2005-01-24
MX9804119A (es) 1998-09-30
PT863917E (pt) 2004-02-27
CN1166597C (zh) 2004-09-15
IS4734A (is) 1998-05-05
SK284392B6 (sk) 2005-03-04
IL119691A0 (en) 1997-02-18
BR9611647A (pt) 1999-02-23
JP2000502055A (ja) 2000-02-22
EA199800492A1 (ru) 1998-12-24
CA2238574A1 (en) 1997-06-05
US5843903A (en) 1998-12-01
DK0863917T3 (da) 2004-01-19
NO982252L (no) 1998-05-15
JP3987575B2 (ja) 2007-10-10
HK1017363A1 (en) 1999-11-19
ES2310222T3 (es) 2009-01-01
HU229870B1 (en) 2014-10-28
DE69637604D1 (de) 2008-08-28
CN1137136C (zh) 2004-02-04
PL187230B1 (pl) 2004-06-30
CA2471775A1 (en) 1997-06-05
JP2007045845A (ja) 2007-02-22
SK284672B6 (sk) 2005-08-04
DE69630233D1 (de) 2003-11-06
IS8567A (is) 2006-11-09
ATE401305T1 (de) 2008-08-15
CA2471775C (en) 2008-01-29

Similar Documents

Publication Publication Date Title
MY120994A (en) 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives
IS8567A (is) Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi
MX9800411A (es) Compuestos quimicos.
YU49389B (sh) Postupak odorisanja gasa
NO952869L (no) Aminosyrederivater, medikamenter inneholdende disse forbindelser og fremgangsmåter for fremstilling derav
NO971903L (no) Krystallisering av levobupivacain og analoger derav
NO962177L (no) Fremgangsmåte for inhibering av hvitt belegg på bearbeidede gulrötter
DE69327166D1 (de) N-(dihydroxyalkyl)-ethinylalanin-amide mit endständiger azacyclyl-gruppe für die behandlung von bluthochdruck
JPS51125755A (en) A method for treating hyperpiesia
ATE163951T1 (de) Verfahren zur herstellung von polyasparaginsäure und/oder polyasparaginsäureimiden
FR2405650A1 (fr) Application de la (l) phenyl alanine a la lutte contre les tracheomycoses des vegetaux
JPS5215891A (en) Method for preparing l-amino acids
EP0347136A3 (en) Method for reducing aromatic nitro groups
JPS51140816A (en) Alloy tool steel
UA12764A (uk) Спосіб одержаhhя гідрохлориду гуаhілтіосечовиhи
JPS5294476A (en) Method of immobilizing microorganisms
DE69326555D1 (de) Ethynyl-alanin-aminodiolverbindungen mit piperazinylendgruppe oder piperazinyl-alkylamino-endgruppe zur behandlung von bluthochdruck
JPS5233635A (en) 2-(omega-aminoalkoxy)diphenylethers
JPS5411142A (en) Production of water-soluble coating
ES8106698A1 (es) Procedimiento de obtencion de esteres de derivados hidrosi- alquilarilicos.
HUP9902110A2 (hu) Eljárás szubsztituált aromás tiokarbonsavamidok előállítására
ES8207516A1 (es) Procedimiento para la obtencion de acido acetilaminometil- fosfonico
JPS5372145A (en) Trouble spot standardization device
JPS51141458A (en) Method of treating aqueous ammonia solution
JPS5247504A (en) Nitrogen-containing powder-sintered high speed steel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application